⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Gold Declines as Pfizer Plans to File for U.S. Vaccine Approval

Published 18/11/2020, 13:28
©  Reuters
XAU/USD
-
XAG/USD
-
PFE
-
GC
-
SI
-
PL
-
BNTX
-

(Bloomberg) -- Gold fell after Pfizer Inc. (NYSE:PFE) announced plans to file for an emergency authorization after a final analysis showed its shot had no significant safety issues.

The U.S. drugmaker and partner BioNTech SE (NASDAQ:BNTX) said their Covid-19 vaccine was 95% effective, paving the way for them to file for authorization in the U.S. “within days.” Bullion has carved out a trading range below $1,900 an ounce since Pfizer announced an initial readout on the vaccine’s effectiveness last Monday, blunting demand for the haven.

Even with effective vaccines in the pipeline, the U.S. faces an uphill battle to bring the pandemic under control. While states including California and Illinois have extended restrictions to combat rising case numbers, an aid package from Congress could take time. Speaker Nancy Pelosi and Senate Minority Leader Chuck Schumer on Tuesday asked Senate Majority Leader Mitch McConnell to resume talks for further fiscal stimulus, though McConnell stuck to his insistence on a targeted package.

“Lockdowns are spreading across the U.S. and with no immediate signs that Congress is ready to break the stimulus stalemate, gold will continue to struggle to rise,” said Edward Moya, a senior market analyst at Oanda Corp.

Exchange-traded funds, a key driver of gold’s rally to a record this year, have dropped about 40 tons of metal since the news, a sign investor confidence may be dwindling. Prices are yet to experience a protracted decline though, due to expectations that central banks will step up to help economies.

Spot gold declined 0.4% to $1,872.03 an ounce at 12:28 p.m. in London, after retreating 0.5% on Tuesday. Silver and Platinum also dropped. The Bloomberg Dollar Spot Index declined 0.1% after ending Tuesday at the lowest level since April 2018.

©2020 Bloomberg L.P.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.